Over a million cases of Cutaneous Squamous Cell Carcinoma are diagnosed annually. For eligible patients, surgery has been the primary treatment modality in part due to high cure rates. Patients ineligible for surgery have often been left with a dismal set of options. New therapeutic modalities, however, are now changing the way clinicians’ approach cSCC, particularly for tumors unamenable to surgery. Join medical oncologists, dermatologists, and Mohs surgeons as they explore the safety and efficacy of emerging systemic therapies, including conversations with patients and caregivers.